Third Rock goes bi-coastal, pumping $41M into SF blood diseases start-up
This article was originally published in Scrip
Executive Summary
The latest start-up backed by Third Rock Ventures, Global Blood Therapeutics, has come out of stealth mode after two years. With a Series A funding of $40.7 million, Third Rock, a prolific early-stage investor in East Coast startups, is now funding its first "de novo" startup on the West Coast. Global Blood Therapeutics, based in San Francisco, aims to find oral small molecule drugs to treat severe, genetic blood diseases. With a new West Coast office, the venture firm now hopes to operate with an expanded, bi-coastal model.